Steinhart Richard I 4
4 · BioXcel Therapeutics, Inc. · Filed Dec 15, 2025
Insider Transaction Report
Form 4
Steinhart Richard I
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-12-14+33→ 6,542 total - Exercise/Conversion
Common Stock
2025-12-15+35→ 6,577 total - Exercise/Conversion
Restricted Stock Units
2025-12-14−33→ 130 total→ Common Stock (33 underlying) - Exercise/Conversion
Restricted Stock Units
2025-12-15−35→ 282 total→ Common Stock (35 underlying)
Footnotes (3)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]On March 14, 2022, the Reporting Person was granted 521 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.
- [F3]On March 15, 2023, the Reporting Person was granted 562 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.